Wednesday, July 8, 2026

Patent intelligence · US

US 10172786

Oral care composition comprising cannabinoids

granted A61KA61K2800/28A61K31/352A61K31/658
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 12
Applicant portfolio 138
Patent details — US 10172786
Jurisdiction
US
Status
granted
Grant date
Jan 8, 2019
Expiration
Jan 3, 2039
Claims
5
CPC classes
A61K, A61K2800/28, A61K31/352, A61K31/658
View on Google Patents ↗

Quick answer

US 10172786 (Oral care composition comprising cannabinoids) is held by AXIM BIOTECHNOLOGIES. INC.. Status: granted. Granted Jan 8, 2019. Expires Jan 3, 2039 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
5
CPC classes
A61K, A61K2800/28, A61K31/352, A61K31/658, A61K8/19, A61K8/25

More from AXIM BIOTECHNOLOGIES. INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12391732

    Articles comprising a silk polypeptide for antigen delivery

    Ludwig-Maximilians-Universitat Munchen · Expires Aug 14, 2045

    granted
  2. US 12379385

    Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function

    Maximus Diagnostic Technologies LLC · Expires Jul 31, 2045

    granted
  3. US 12318397

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Expires May 29, 2045

    granted
  4. US 12290524

    Methods and compositions for testosterone production

    Maximus Health, Inc. · Expires May 1, 2045

    granted
  5. US 12171837

    Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates

    Ludwig-Maximilians-Universitat Munchen · Expires Dec 19, 2044

    granted
  6. US 12168718

    Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel

    Julius-Maximilians-Universitat Wurzburg · Expires Dec 12, 2044

    granted
  7. US 12144876

    Security mechanisms for radiopharmaceutical elution system and elution process

    Jubilant Draximage Inc. · Expires Nov 14, 2044

    granted
  8. US 12133890

    Antigen-binding polypeptide targeting B7H3 and application thereof

    NINGBO T-MAXIMUM BIOPHARMACEUTICALS CO., LTD. · Expires Oct 31, 2044

    granted

Frequently asked questions

What is US patent 10172786?

US 10172786 (Oral care composition comprising cannabinoids) is held by AXIM BIOTECHNOLOGIES. INC.. Status: granted. Granted Jan 8, 2019. Expires Jan 3, 2039 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10172786?

AXIM BIOTECHNOLOGIES. INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.

When does US 10172786 expire?

Our index shows an expiration date of Jan 3, 2039 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.